These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. Motomura W; Nagamine M; Tanno S; Sawamukai M; Takahashi N; Kohgo Y; Okumura T J Gastroenterol; 2004; 39(5):461-8. PubMed ID: 15175945 [TBL] [Abstract][Full Text] [Related]
5. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480 [TBL] [Abstract][Full Text] [Related]
7. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223 [TBL] [Abstract][Full Text] [Related]
8. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302 [TBL] [Abstract][Full Text] [Related]
9. Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. Begum NM; Nakashiro K; Kawamata H; Uchida D; Shintani S; Ikawa Y; Sato M; Hamakawa H Int J Oncol; 2002 Mar; 20(3):599-605. PubMed ID: 11836575 [TBL] [Abstract][Full Text] [Related]
10. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093 [TBL] [Abstract][Full Text] [Related]
11. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389 [TBL] [Abstract][Full Text] [Related]
12. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Takeuchi S; Okumura T; Motomura W; Nagamine M; Takahashi N; Kohgo Y Jpn J Cancer Res; 2002 Jul; 93(7):774-82. PubMed ID: 12149143 [TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743 [TBL] [Abstract][Full Text] [Related]
14. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613 [TBL] [Abstract][Full Text] [Related]
15. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665 [TBL] [Abstract][Full Text] [Related]
16. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999 [TBL] [Abstract][Full Text] [Related]
18. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441 [TBL] [Abstract][Full Text] [Related]
19. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Itami A; Watanabe G; Shimada Y; Hashimoto Y; Kawamura J; Kato M; Hosotani R; Imamura M Int J Cancer; 2001 Nov; 94(3):370-6. PubMed ID: 11745416 [TBL] [Abstract][Full Text] [Related]
20. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Sato H; Ishihara S; Kawashima K; Moriyama N; Suetsugu H; Kazumori H; Okuyama T; Rumi MA; Fukuda R; Nagasue N; Kinoshita Y Br J Cancer; 2000 Nov; 83(10):1394-400. PubMed ID: 11044367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]